| 2/28/2025 | CV | BridgeBio greenshoe lifts 1.75% convertibles to $575 million
|
| 2/26/2025 | CV | Market Commentary: BridgeBio, Cheesecake Factory jump on debut; Lucid falls; CleanSpark under pressure
|
| 2/26/2025 | CV | Market Commentary: Morning Commentary: BridgeBio, Cheesecake Factory convertible notes jump on debut
|
| 2/26/2025 | CV | New Issue: BridgeBio prices $500 million six-year convertible notes to yield 1.75%, up 45%
|
| 2/25/2025 | CV | Market Commentary: BridgeBio, Cheesecake Factory convertibles play to strong demand; Unity volatile
|
| 2/25/2025 | CV | BridgeBio tightens talk on $500 million six-year convertibles to yield 1.75%, up 42.5%-45%
|
| 2/25/2025 | CV | Market Commentary: Morning Commentary: BridgeBio, Cheesecake Factory convertible offerings eyed; Unity up
|
| 2/24/2025 | CV | Market Commentary: BridgeBio, Cheesecake Factory on deck; Unity plays to heavy demand; Alibaba up on hedge
|
| 2/24/2025 | CV | BridgeBio talks $500 million six-year convertible notes to yield 1.75%-2.25%, up 37.5%-42.5%
|
| 6/24/2024 | CV | Market Commentary: SolarEdge on deck; Liberty/Charter exchangeables eyed; Alnylam convertible notes soar
|
| 1/18/2024 | CV | Market Commentary: Winnebago convertibles play to strong demand; BrightSpring on deck; BridgeBio active
|
| 1/18/2024 | CV | Market Commentary: Morning Commentary: Winnebago convertible notes offering eyed; BrightSpring on deck
|
| 8/28/2023 | CV | Market Commentary: Convertibles secondary activity at a crawl; BridgeBio lower; PROS higher; DISH active
|
| 7/19/2023 | CV | Market Commentary: Carvana drops following exchange offer; Luminar convertible notes up; BridgeBio better
|
| 7/19/2023 | CV | Market Commentary: Morning Commentary: Carvana in focus on exchange offer; Luminar convertible notes up
|
| 7/18/2023 | CV | Market Commentary: Convertible bond primary quiet; LG Chem notes set to trade; BridgeBio Pharma higher
|
| 7/18/2023 | CV | Market Commentary: Morning Commentary: Convertibles primary quiet; LG Chem notes set to trade; BridgeBio up
|
| 7/17/2023 | CV | Market Commentary: Biopharma names up in convertibles action; EV truck makers woeful as competition rises
|
| 3/6/2023 | CV | Market Commentary: Rivian on deck; BridgeBio convertible notes skyrocket on clinical trial; PPL active
|
| 3/6/2023 | CV | Market Commentary: Morning Commentary: BridgeBio convertible notes skyrocket outright on clinical trial
|
| 7/1/2022 | CV | Market Commentary: Cytokinetics convertibles price, skyrocket on debut; Etsy gains; BridgeBio hits new low
|
| 1/3/2022 | CV | Market Commentary: Lucid convertibles improve on strong day for EV makers; BridgeBio bounces off lows
|
| 2/2/2021 | CV | Market Commentary: Mitek Systems convertible offering eyed; Travere notes active; BridgeBio rebounds
|
| 1/29/2021 | CV | BridgeBio greenshoe lifts 2.25% convertibles to $747.5 million
|
| 1/27/2021 | CV | Market Commentary: Marriott Vacations, Two Harbors eyed; BridgeBio tanks; Cinemark convertibles soar
|
| 1/26/2021 | CV | Market Commentary: Marriott, Two Harbors on deck; BridgeBio, Sunrun in focus, trade up; Alarm.com active
|
| 1/26/2021 | CV | Market Commentary: Morning Commentary: BridgeBio, Sunrun convertible notes in focus, trade up on debut
|
| 1/26/2021 | CV | New Issue: BridgeBio sells upsized $650 million eight-year convertibles to yield 2.25%, up 47.5%
|
| 1/25/2021 | CV | Market Commentary: BridgeBio upsizes convertibles, tightens talk; Sunrun eyed; 21Vianet, Bentley soar
|
| 1/25/2021 | CV | BridgeBio tightens talk on upsized eight-year convertible notes
|
| 1/25/2021 | CV | Market Commentary: Morning Commentary: Planned BridgeBio Pharma, SunRun convertible offerings eyed
|
| 1/25/2021 | CV | BridgeBio talks $400 million eight-year convertible notes to yield 2.25%-2.75%, up 32.5%-37.5%
|
| 3/10/2020 | CV | BridgeBio Pharma greenshoe lifts convertibles to $550 million
|
| 3/6/2020 | CV | Market Commentary: Cypress drops outright, expands dollar-neutral; BridgeBio weakens; NanoString gains
|
| 3/5/2020 | CV | Market Commentary: Convertibles primary prices $1.2 billion in four deals; BridgeBio, NanoString soar
|
| 3/5/2020 | CV | Market Commentary: Morning Commentary: Convertibles primary market prices $1.2 billion in four deals
|
| 3/5/2020 | CV | New Issue: BridgeBio Pharma sells upsized $475 million seven-year convertibles at 2.5%, up 37.5%
|
| 3/4/2020 | CV | Market Commentary: Infinera, Enphase, NanoString Technologies, BridgeBio convertible note offerings eyed
|
| 3/4/2020 | CV | Market Commentary: Morning Commentary: Infinera, Enphase, NanoString Technologies, BridgeBio notes on tap
|
| 3/4/2020 | CV | BridgeBio Pharma talks $350 million seven-year convertibles to yield 2.25%-2.75%, up 35%-40%
|
